NCT06945458View on ClinicalTrials.gov

Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 17, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Atopic Dermatitis
Interventions
DRUG

KT-621

Oral drug

Trial Locations (12)

29420

Kymera Investigative Site, Charleston

33024

Kymera Investigative Site, Hollywood

33436

Kymera Investigative Site, Boynton Beach

33613

Kymera Investigative Site, Tampa

35244

Kymera Investigative Site, Birmingham

43016

Kymera Investigative Site, Dublin

45505

Kymera Investigative Site, Springfield

58078

Kymera Investigative Site, Fargo

74136

Kymera Investigative Site, Tulsa

78213

Kymera Investigative Site, San Antonio

90404

Kymera Investigative Site, Santa Monica

92708

Kymera Investigative Site, Fountain Valley

Sponsors
All Listed Sponsors
lead

Kymera Therapeutics, Inc.

INDUSTRY

NCT06945458 - Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD) | Biotech Hunter | Biotech Hunter